GlaxoSmithKline

Pertinax Pharma appoints former Sanofi chairman Nigel Brooksby as Chairman

Tuesday, November 14, 2017

Pertinax Pharma announces that Nigel Brooksby has been appointed as chairman of the company. His chief responsibilities will be to assist in corporate, strategic and business development moves into its commercialization phase following the launch last month of Pertinax. This unique technology which enables controlled and sustained release of the antimicrobial, chlorhexidine (CHX) has wide ranging potential applications, spanning the wound care, medical device, dental and veterinary markets.

[Read More]

Partnership aims to accelerate development of new immunotherapy strategies

Monday, October 23, 2017

The Partnership for Accelerating Cancer Therapies (PACT) has launched thanks to a partnership between the NIH and 11 biopharmaceutical companies. The goal of the new partnership is to accelerate the development of new cancer immunotherapy strategies for more patients in half the time. The initiative specifically aims to explore the question: Why doesn’t immunotherapy work for all cancers, in all patients, and what can be done about it?

[Read More]

NIH partners with 11 biopharmaceutical companies on cancer immunotherapy strategies

Friday, October 13, 2017

The NIH and 11 biopharmaceutical companies launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers—standardized biological markers of disease and treatment response—to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role. 

[Read More]

GSK announces phase III results of mepolizumab for eosinophilic COPD

Wednesday, September 13, 2017

GlaxoSmithKline announced the publication of full results from the phase III studies for mepolizumab in chronic obstructive pulmonary disease (COPD). Data from the investigational clinical development program showed that treating eosinophilic COPD patients with the biologic medicine, mepolizumab, in addition to maximal guideline-recommended therapy, reduced exacerbations in these difficult-to-treat patients. Based on the full data, discussions with external experts and the recognized unmet medical need in this patient population, regulatory filings are planned for 2017. Mepolizumab is not approved for use anywhere in the world for COPD.

[Read More]

Propeller Health expands digital health collaboration with GlaxoSmithKline

Friday, August 25, 2017

Propeller Health, a digital solution for respiratory medicine, announced the expansion of its 2015 collaboration with GSK, enabling both companies to prepare for and undertake commercial activities using the Propeller clip-on sensor and software platform for use with GSK’s ELLIPTA Inhaler. The companies will continue ongoing research and development efforts to collect evidence from the Propeller clip-on sensor and software platform used in conjunction with GSK’s respiratory medicines for asthma and COPD.

[Read More]

Adimab announces platform transfer with Lilly

Friday, July 21, 2017

Adimab, a global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, has entered into an agreement with Eli Lilly to transfer the Adimab Platform to Lilly for the discovery and optimization of antibody-based drugs in all therapeutic areas. This technology transfer expands an ongoing collaboration between the two companies that was initiated in 2010, which has yielded several undisclosed therapeutic candidates for Lilly.

[Read More]